CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cyfuse Biomedical KK is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cyfuse Biomedical KK
5A, ICN Bldg., 2-27-17, Hongo
Phone: +81 364351885p:+81 364351885 MINATO-KU, TKY  108-6301  Japan Ticker: 48924892
Business Summary
Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive President, Chief Executive Officer, Representative Director ShizukaAkieda 46 3/1/2018 9/1/2016
Chief Financial Officer, Executive Officer, Director MasahiroSanjo 46 3/1/2018 10/1/2017
Executive Officer, Director of System Development, Director NorihikoTokunaga 47 3/1/2021 3/1/2019
Independent Director KunihikoSuzuki 64 3/1/2021 3/1/2021
Independent Director YasuhiroYoshioka 67 3/1/2019 3/1/2019

General Information
Number of Employees: 21 (As of 12/31/2023)
Outstanding Shares: 7,901,300 (As of 2/29/2024)
Shareholders: 6,647
Stock Exchange: TYO
Fax Number: +81 364351883


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024